Boston- and Shenzhen-based pharma firm XtalPi, which uses AI for drug discovery and development, raises $15M Series B from Sequoia China, Google, and Tencent
Cate Cadell / Reuters :
Context & Ripple Effects
In January 2018, XtalPi's $15M Series B was an early bet on applying AI to drug discovery, backed by an unusual trio: Sequoia China on the venture side plus Google and Tencent as corporate strategics, giving the Boston-Shenzhen company capital and credibility across both ecosystems.
The bet compounded fast: XtalPi went on to raise a $319M Series C led by SoftBank's Vision Fund in 2020 and then a $400M Series D at a valuation above $2B in 2021, while peers like Insilico and DP Technology followed similar funding paths — making this round the template for how US and Chinese capital jointly seeded the sector.
First-order effects
- XtalPi gains runway and two of the most valuable corporate networks in tech — Google and Tencent — at a stage when its AI-driven discovery platform is still unproven commercially.
Second-order effects
- The round legitimizes AI drug discovery for later-stage capital: within roughly two years SoftBank's Vision Fund writes a check more than twenty times this size, and rivals such as Insilico raise comparable mega-rounds on the same thesis.
Third-order effects
- By 2025 the pattern matures into commercial validation, with Western pharma giants striking multibillion-dollar deals with Chinese biotech firms using AI — turning what was a speculative 2018 venture bet into a recognized pillar of global drug R&D sourcing.
The trend: AI drug discovery in China is scaling from small dual-market venture bets into billion-dollar platforms funded first by joint US-China capital and later validated by Western pharma licensing deals.